Michael Prosser

About

TwinEdge Bioscience is a techbio company dedicated to the development of digital twins for oncology drug discovery and development. By delivering population scale insight earlier in the drug development process, we enable our clients make better decisions regarding which translational programmes progress to clinical trials, and how those clinical trials are designed and run. Combining cutting-edge computational biology, artificial intelligence, and personalized medicine, TwinEdge Bioscience is transforming how new cancer therapies are developed.

Experience

• TwinEdge Bioscience (1 yr 8 mos)
  • Advisor
    May 2026 - Present · 2 mos

  • CEO & Co-founder
    Nov 2024 - May 2026 · 1 yr 7 mos

• Owner at Cairnstone Life Sciences
  May 2024 - Present · 2 yrs 2 mos

  Consulting and management services

• Managing Director at Indivumed Services
  Apr 2023 - Jun 2024 · 1 yr 3 mos

• Board Member at Crown Bioscience & MBL
  Sep 2022 - Jun 2024 · 1 yr 10 mos

• Crown Bioscience (13 yrs 4 mos)
  • Chief Business Officer / SVP
    Apr 2020 - Jun 2024 · 4 yrs 3 mos

  • Vice President, Corporate Development and Strategy
    Feb 2018 - Apr 2020 · 2 yrs 3 mos

  • Vice President/GM Operations, Europe and North America
    Apr 2016 - Apr 2018 · 2 yrs 1 mo